Table 5 Antidiabetic drug use, by maternal age, in livebirth pregnancies among women with pre-existing diabetes during 2001–2013 in the MSDD
|  | < 20 years | 20–24 years | 25–29 years | 30–34 years | 35–39 years | 40–44 years | 45–54 years |
|---|---|---|---|---|---|---|---|
Total unique pregnancies | 404 (100%) | 1608 (100%) | 3545 (100%) | 4949 (100%) | 3745 (100%) | 1082 (100%) | 273 (100%) |
Drug product/Class | |||||||
 Any Antidiabetic Drug | 365 (90.35%) | 1419 (88.25%) | 3262 (92.02%) | 4635 (93.66%) | 3536 (94.42%) | 1010 (93.35%) | 261 (95.60%) |
 Alpha-Glucosidase Inhibitors | 0 (0.00%) | 2 (0.12%) | 8 (0.23%) | 9 (0.18%) | 3 (0.08%) | 4 (0.37%) | 2 (0.73%) |
 Amylin Analog | 1 (0.25%) | 3 (0.19%) | 14 (0.39%) | 17 (0.34%) | 6 (0.16%) | 3 (0.28%) | 0 (0.00%) |
 Metformin | 87 (21.53%) | 311 (19.34%) | 1102 (31.09%) | 1906 (38.51%) | 1722 (45.98%) | 598 (55.27%) | 160 (58.61%) |
 Dipeptidyl Peptidase-4 Inhibitors | 1 (0.25%) | 3 (0.19%) | 32 (0.90%) | 66 (1.33%) | 75 (2.00%) | 27 (2.50%) | 19 (6.96%) |
 Glucagon-like Peptide-1 Receptor Agonists | 3 (0.74%) | 11 (0.68%) | 56 (1.58%) | 103 (2.08%) | 94 (2.51%) | 34 (3.14%) | 15 (5.49%) |
 Meglitinide Analogs | 1 (0.25%) | 7 (0.44%) | 8 (0.23%) | 13 (0.26%) | 9 (0.24%) | 3 (0.28%) | 2 (0.73%) |
 Sulfonylureas | 28 (6.93%) | 184 (11.44%) | 512 (14.44%) | 907 (18.33%) | 833 (22.24%) | 255 (23.57%) | 84 (30.77%) |
 Thiazolidinediones | 14 (3.47%) | 64 (3.98%) | 181 (5.11%) | 246 (4.97%) | 187 (4.99%) | 68 (6.28%) | 40 (14.65%) |
 Combination Products | 6 (1.49%) | 37 (2.30%) | 84 (2.37%) | 155 (3.13%) | 155 (4.14%) | 43 (3.97%) | 22 (8.06%) |
 Insulin | 321 (79.46%) | 1237 (76.93%) | 2701 (76.19%) | 3767 (76.12%) | 2868 (76.58%) | 789 (72.92%) | 113 (41.39%) |